Attached files

file filename
EX-99.1 - PRESS RELEASE DATED FEBRUARY 5, 2015 - UROLOGIX INCurologix150439_ex99-1.htm

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
     
FORM 8-K 
     
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (date of earliest event reported): February 5, 2015
     
Urologix, Inc.
(Exact name of Registrant as Specified in its Charter)
 
Minnesota
(State Or Other Jurisdiction Of Incorporation)
             
 
000-28414
     
41-1697237
 
 
(Commission File Number)
     
(I.R.S. Employer Identification No.)
 

             
 
14405 21st Avenue North
     
55447
 
 
Minneapolis, MN
     
(Zip Code)
 
 
(Address Of Principal Executive Offices)
         
 
(763) 475-1400
Registrant’s Telephone Number, Including Area Code
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
   
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 

 

 
 
Items under Sections 1, 3, 4, 5, 6, 7 and 8 are not applicable and are therefore omitted.
   
ITEM 2.02
RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
 
Urologix, Inc. (the “Company”) hereby furnishes as Exhibit 99.1 a press release issued on February 5, 2015 disclosing material non-public information regarding the Company’s results of operations for the second fiscal quarter of fiscal year 2015 ended December 31, 2014.
   
ITEM 9.01
FINANCIAL STATEMENTS AND EXHIBITS.
   
Exhibit No.
 
Description
 
99.1
Press Release Issued on February 5, 2015.
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
 
UROLOGIX, INC.
 
       
 
By:
/s/ Gregory J. Fluet
   
Gregory J. Fluet
 
   
Chief Executive Officer
 
       
Date: February 5, 2015